ASCO 2026: Latest in prostate cancer

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission

MCED blood test trial fails primary end point, but screening cut number of cancers found at stage IV

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

177Lu-rosopatamab plus standard of care shows manageable safety and favourable tumour targeting in mCRPC

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma

Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps

Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours

Implanted tile-based radiation shows promise compared with stereotactic radiotherapy for brain metastases